Table 2.
Detailed clinicopathological findings and prognosis in 42 of liver-involving B-cell lymphoma
| Histological type | Clinical stage | Liver disease | Hepatic tumors | Complication | Median survival (months) | ||||
|---|---|---|---|---|---|---|---|---|---|
| I/II/III/IV | CH | LC | HCC | Single | Multiple | Diffuse | |||
| Primary hepatic B-cell lymphoma | |||||||||
| DLBCL: 12 | 7/5/0//0 | 5 | 3 | 1 | 8 | 4 | 0 | RA: 2 | 27 |
| MALT: 8 | 8/0/0//0 | 3 | 1 | 1 | 8 | 0 | 0 | SS: 2, PBC: 1a, AH: 1 | >84 |
| Total: 20 | 15/5/0//0 | 8 | 4 | 2 | 16 | 4 | 0 | 6 | |
| Liver-involving systemic B-cell lymphoma | |||||||||
| IVLBCL: 12 | 0/0/0//12 | 1 | 0 | 0 | 0 | 0 | 12 | SLE: 1 | 6 |
| DLBCL: 10 | 0/0/0//10 | 5 | 0 | 0 | 2 | 8 | 0 | 0 | 13 |
| Total 22 | 0/0/0//22 | 6 | 0 | 0 | 2 | 8 | 12 | 1 | |
DLBCL diffuse large B-cell lymphoma, MALT mucosa-associated lymphoid tissue, IVLBCL intravascular large B-cell lymphoma, CH chronic hepatitis, LC liver cirrhosis, HCC hepatocellular carcinoma, RA rheumatoid arthritis, SS Sjögren’s syndrome, PBC primary biliary cirrhosis, AH autoimmune hepatitis, SLE systemic lupus erythematosus
aOne patient complicates PBC and SS